Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients with Avian Influenza A(H7N9) Virus

Clinical Infectious Diseases

Volumn 66, Issue 7, 2018, Pages 1054-1060

  Zheng, Shufa ^a,b,c   Tang, Lingling ^a   Gao, Hainv ^a   Wang, Yiyin ^b,c   Yu, Fei ^b,c   Cui, Dawei ^b,c   Xie, Guoliang ^b,c   Yang, Xianzhi ^b,c   Zhang, Wen ^b,c   Ye, Xianfei ^b,c   Zhang, Zike ^b,c   Wang, Xi ^d   Yu, Liang ^a   Zhang, Yiming ^a   Yang, Shigui ^a   Liang, Weifeng ^a   Chen, Yu ^a,b,c   Li, Lanjuan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Key Laboratory of Clinical in vitro Diagnostic Techniques of Zhejiang Province   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d Ministry of Health   (Singapore)

Author keywords

H7N9; Influenza; Neuraminidase inhibitor treatment; Viral shedding

Indexed keywords

CORTICOSTEROID; OSELTAMIVIR; PERAMIVIR; PRESCRIPTION DRUG; VIRUS RNA; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE;

ACUTE KIDNEY FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGE; AGED; ANTIVIRAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; AUTOIMMUNE DISEASE; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OUTCOME; COHORT ANALYSIS; COMBINATION DRUG THERAPY; CORRELATION COEFFICIENT; CORTICOSTEROID THERAPY; CRITICALLY ILL PATIENT; DIABETES MELLITUS; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; EARLY INTERVENTION; EXTRACORPOREAL OXYGENATION; FEMALE; HEART FAILURE; HEMATOLOGIC DISEASE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HYPERTENSION; INFLUENZA A (H7N9); INFLUENZA A VIRUS (H7N9); ISCHEMIC HEART DISEASE; LENGTH OF STAY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MORTALITY; OBSERVATIONAL STUDY; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOLYSIS; SEASONAL VARIATION; SEX; SHOCK; SPRING; SURVIVAL; TIME TO TREATMENT; TREATMENT DURATION; TREND STUDY; VIRUS LOAD; VIRUS SHEDDING; WINTER; CHINA; DRUG EFFECT; HOSPITALIZATION; INFLUENZA; MIDDLE AGED; SEASON; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTIVIRAL AGENTS; CHINA; ENZYME INHIBITORS; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEURAMINIDASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEASONS; TIME FACTORS; TREATMENT OUTCOME; VIRUS SHEDDING;

EID: 85044196484     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix930     Document Type: Article

References (25)

1. Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368:1888-97.
2. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368:2277-85.
3. Li Q, Zhou L, Zhou M, et al. Epidemiology of human infections with avian influenza A(H7N9) virus in China. N Engl J Med 2014; 370:520-32.
4. Chen Y, Liang W, Yang S, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet 2013; 381:1916-25.
5. National Health and Family Planning Commission of the People's Republic of China. National Notifiable Infectious Disease Report. Available at: http:// www.nhfpc.gov.cn/jkj/s3578/201702/f1e4cfe184e44f80ae57d0954c3d5 fce.shtml. Accessed 21 April 2017.
6. Rosen JB, Rota JS, Hickman CJ, et al. Outbreak of measles among persons with prior evidence of immunity, New York City, 2011. Clin Infect Dis 2014; 58:1205-10.
7. Farooqui A, Huang L, Wu S, et al. Assessment of antiviral properties of peramivir against H7N9 avian influenza virus in an experimental mouse model. Antimicrob Agents Chemother 2015; 59:7255-64.
8. World Health Organization. Avian influenza A(H7N9) virus: post-exposure antiviral chemoprophylaxis of close contacts of a patient with confirmed H7N9 virus infection and/or high risk poultry/environmental exposures. Available at: http:// www.who.int/entity/influenza/human-animal-interface/influenza-h7n9/13- January-2013-PEP-recs.pdf?ua=1. Accessed 21 April 2017.
9. National Health and Family Planning Commission of People's Republic of China. Protocol for prevention and control of the A(H7N9) human infection outbreak. 3rd ed. Available at: http://www.nhfpc.gov.cn/jkj/s3577/201401/ 8c1828375a7949cd85454a76bb84f23a.shtml. Accessed 21 April 2017.
10. Muthuri SG, Venkatesan S, Myles PR, et al; PRIDE Consortium Investigators. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395-404.
11. McGeer A, Green KA, Plevneshi A, et al; Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568-75.
12. Lee N, Cockram CS, Chan PK, Hui DS, Choi KW, Sung JJ. Antiviral treatment for patients hospitalized with severe influenza infection may affect clinical outcomes. Clin Infect Dis 2008; 46:1323-4.
13. Aoki FY, Macleod MD, Paggiaro P, et al; IMPACT Study Group. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51:123-9.
14. Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis 2010; 51:887-94.
15. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363-73.
16. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of influenza A virus infection in humans. J Virol 2006; 80:7590-9.
17. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492-500.
18. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J Infect Dis 2010; 202:1154-60.
19. Chen Y, Wang D, Zheng S, et al. Rapid diagnostic tests for identifying avian influenza A(H7N9) virus in clinical samples. Emerg Infect Dis 2015; 21:87-90.
20. Thomas BJ, Porritt RA, Hertzog PJ, Bardin PG, Tate MD. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Sci Rep 2014; 4:7176.
21. Cao B, Gao H, Zhou B, et al. Adjuvant corticosteroid treatment in adults with influenza A (H7N9) viral pneumonia. Crit Care Med 2016; 44:e318-28.
22. Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381:2273-9.
23. Marjuki H, Mishin VP, Chesnokov AP, et al. Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan. J Infect Dis 2015; 211:249-57.
24. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 2006; 70:121-31.
25. Zhang Y, Gao H, Liang W, et al. Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for influenza A (H7N9) infection: a retrospective study. BMC Infect Dis 2016;16:76.